392 related articles for article (PubMed ID: 25648577)
21. Variable Contribution of Heart Failure to Quality of Life in Ambulatory Heart Failure With Reduced, Better, or Preserved Ejection Fraction.
Joyce E; Chung C; Badloe S; Odutayo K; Desai A; Givertz MM; Nohria A; Lakdawala NK; Stewart GC; Young M; Weintraub J; Stevenson LW; Lewis EF
JACC Heart Fail; 2016 Mar; 4(3):184-93. PubMed ID: 26874379
[TBL] [Abstract][Full Text] [Related]
22. Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial.
Nolte K; Herrmann-Lingen C; Wachter R; Gelbrich G; Düngen HD; Duvinage A; Hoischen N; von Oehsen K; Schwarz S; Hasenfuss G; Halle M; Pieske B; Edelmann F
Eur J Prev Cardiol; 2015 May; 22(5):582-93. PubMed ID: 24627449
[TBL] [Abstract][Full Text] [Related]
23. Predictors of the quality of life of older people with heart failure recruited from primary care.
Gott M; Barnes S; Parker C; Payne S; Seamark D; Gariballa S; Small N
Age Ageing; 2006 Mar; 35(2):172-7. PubMed ID: 16495294
[TBL] [Abstract][Full Text] [Related]
24. Comorbid Conditions and Health-Related Quality of Life in Ambulatory Heart Failure Patients: REVIVAL (Registry Evaluation of Vital Information for VADs in Ambulatory Life REVIVAL).
Cascino TM; Kittleson MM; Lala A; Stehlik J; Palardy M; Pamboukian SV; Ewald GA; Mountis MM; Horstmanshof DA; Robinson SW; Shah P; Jorde UP; McLean RC; Richards B; Khalatbari S; Spino C; Taddei-Peters WC; Grady KL; Mann DL; Stevenson LW; Stewart GC; Aaronson KD;
Circ Heart Fail; 2020 May; 13(5):e006858. PubMed ID: 32418478
[TBL] [Abstract][Full Text] [Related]
25. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
[TBL] [Abstract][Full Text] [Related]
26. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.
Desai AS; Lewis EF; Li R; Solomon SD; Assmann SF; Boineau R; Clausell N; Diaz R; Fleg JL; Gordeev I; McKinlay S; O'Meara E; Shaburishvili T; Pitt B; Pfeffer MA
Am Heart J; 2011 Dec; 162(6):966-972.e10. PubMed ID: 22137068
[TBL] [Abstract][Full Text] [Related]
27. Determinants of change in quality of life in the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD).
Scherer M; Düngen HD; Inkrot S; Tahirović E; Lashki DJ; Apostolović S; Edelmann F; Wachter R; Loncar G; Haverkamp W; Neskovic A; Herrmann-Lingen C
Eur J Intern Med; 2013 Jun; 24(4):333-8. PubMed ID: 23375618
[TBL] [Abstract][Full Text] [Related]
28. Depression is a major determinant of quality of life in patients with chronic systolic heart failure in general practice.
Müller-Tasch T; Peters-Klimm F; Schellberg D; Holzapfel N; Barth A; Jünger J; Szecsenyi J; Herzog W
J Card Fail; 2007 Dec; 13(10):818-24. PubMed ID: 18068614
[TBL] [Abstract][Full Text] [Related]
29. QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.
Joseph J; Claggett BC; Anand IS; Fleg JL; Huynh T; Desai AS; Solomon SD; O'Meara E; Mckinlay S; Pitt B; Pfeffer MA; Lewis EF
JACC Heart Fail; 2016 Jun; 4(6):477-86. PubMed ID: 27039126
[TBL] [Abstract][Full Text] [Related]
30. The influence of age, gender, and race on the prevalence of depression in heart failure patients.
Gottlieb SS; Khatta M; Friedmann E; Einbinder L; Katzen S; Baker B; Marshall J; Minshall S; Robinson S; Fisher ML; Potenza M; Sigler B; Baldwin C; Thomas SA
J Am Coll Cardiol; 2004 May; 43(9):1542-9. PubMed ID: 15120809
[TBL] [Abstract][Full Text] [Related]
31. The Support, Education, and Research in Chronic Heart Failure Study (SEARCH): a mindfulness-based psychoeducational intervention improves depression and clinical symptoms in patients with chronic heart failure.
Sullivan MJ; Wood L; Terry J; Brantley J; Charles A; McGee V; Johnson D; Krucoff MW; Rosenberg B; Bosworth HB; Adams K; Cuffe MS
Am Heart J; 2009 Jan; 157(1):84-90. PubMed ID: 19081401
[TBL] [Abstract][Full Text] [Related]
32. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
Mitter SS; Shah SJ
Curr Atheroscler Rep; 2015 Nov; 17(11):64. PubMed ID: 26408016
[TBL] [Abstract][Full Text] [Related]
33. Associations Between Depressive Symptoms and HFpEF-Related Outcomes.
Chandra A; Alcala MAD; Claggett B; Desai AS; Fang JC; Heitner JF; Liu J; Pitt B; Solomon SD; Pfeffer MA; Lewis EF
JACC Heart Fail; 2020 Dec; 8(12):1009-1020. PubMed ID: 32919912
[TBL] [Abstract][Full Text] [Related]
34. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
Grodin JL; Testani JM; Pandey A; Sambandam K; Drazner MH; Fang JC; Tang WHW
Eur J Heart Fail; 2018 Oct; 20(10):1436-1443. PubMed ID: 29893446
[TBL] [Abstract][Full Text] [Related]
35. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.
Ambrosy AP; Khan H; Udelson JE; Mentz RJ; Chioncel O; Greene SJ; Vaduganathan M; Subacuis HP; Konstam MA; Swedberg K; Zannad F; Maggioni AP; Gheorghiade M; Butler J
Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27140204
[TBL] [Abstract][Full Text] [Related]
36. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial.
Edelmann F; Gelbrich G; Duvinage A; Stahrenberg R; Behrens A; Prettin C; Kraigher-Krainer E; Schmidt AG; Düngen HD; Kamke W; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Wachter R; Pieske B
Int J Cardiol; 2013 Nov; 169(6):408-17. PubMed ID: 24182675
[TBL] [Abstract][Full Text] [Related]
37. Variation in Placebo Effect on Health-Related Quality of Life in Heart Failure (from the TOPCAT Trial).
Khan MS; Kalogeropoulos AP; Butler J
Am J Cardiol; 2020 Jan; 125(1):82-86. PubMed ID: 31748125
[TBL] [Abstract][Full Text] [Related]
38. Relationship of physical function with quality of life in older patients with acute heart failure.
Aladin AI; Whellan D; Mentz RJ; Pastva AM; Nelson MB; Brubaker P; Duncan P; Reeves G; Rosenberg P; Kitzman DW
J Am Geriatr Soc; 2021 Jul; 69(7):1836-1845. PubMed ID: 33837953
[TBL] [Abstract][Full Text] [Related]
39. Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT).
Fudim M; Kelly JP; Brophy TJ; DeVore AD; Hammill BG; Peterson ED; Pitt B; Yancy C; Fonarow GC; Hernandez AF
Am J Cardiol; 2020 Jun; 125(11):1655-1660. PubMed ID: 32273054
[TBL] [Abstract][Full Text] [Related]
40. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
Patel RB; Shah SJ; Fonarow GC; Butler J; Vaduganathan M
Curr Heart Fail Rep; 2017 Aug; 14(4):217-222. PubMed ID: 28647918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
